Evidence map›Paper›PMID 28631135›Full record

Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018

Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.

F Koinis, A Voutsina, A Kalikaki, A Koutsopoulos, E Lagoudaki, E Tsakalaki, E K Dermitzaki, E Kontopodis, A G Pallis, V Georgoulias and 1 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

F KoinisDepartment of Medical Oncology, University General Hospital of Heraklion, Voutes, P.O BOX 1352, 71110, Heraklion, Crete, Greece.
A VoutsinaLaboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece.
A KalikakiLaboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece.
A KoutsopoulosDepartment of Pathology, University General Hospital of Heraklion, Heraklion, Crete, Greece.
E LagoudakiDepartment of Pathology, University General Hospital of Heraklion, Heraklion, Crete, Greece.
E TsakalakiLaboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece.
E K DermitzakiDepartment of Medical Oncology, University General Hospital of Heraklion, Voutes, P.O BOX 1352, 71110, Heraklion, Crete, Greece.
E KontopodisDepartment of Medical Oncology, University General Hospital of Heraklion, Voutes, P.O BOX 1352, 71110, Heraklion, Crete, Greece.
A G PallisLaboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece.
V GeorgouliasDepartment of Medical Oncology, University General Hospital of Heraklion, Voutes, P.O BOX 1352, 71110, Heraklion, Crete, Greece.
A KotsakisDepartment of Medical Oncology, University General Hospital of Heraklion, Voutes, P.O BOX 1352, 71110, Heraklion, Crete, Greece. kotsakis@med.uoc.gr.
University of Crete · GRUniversity Hospital of Heraklion · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErlotinib has been approved for the management of NSCLC patients after failure of the first or subsequent line of chemotherapy. Although the efficacy of erlotinib is clearly associated with the presence of EGFR mutations, there is a subset of patients with EGFR wild-type (EGFRwt) tumors who impressively respond. PATIENTS AND

methodsPatients with EGFRwt NSCLC who received salvage (≥2nd line) treatment with erlotinib for a prolonged period (>6 months), were sought from the database of the Hellenic Oncology Research Group. We retrospectively analyzed the clinical, pathological and molecular characteristics of the patients with available tumor material.

resultsForty-four patients that received erlotinib for >6 months (median 10.1 months) were enrolled in the study. The majority of them were male, never-smokers with adenocarcinoma histology and a good performance status. KRAS and PIK3CA mutations were detected in 21% (9/42 tested) and 13% (4/30 tested) of the patients, respectively. The ALK-EML4 translocation was found in 10% (2/20 tested); there was no patient with HER2 or BRAF mutated tumor. Twelve (54.5%) tumor specimens were considered positive for EGFR-overexpression. Eleven patients experienced a partial response (objective response rate 25%; 95% CI 12-38%) and the remaining 33 had stable disease. The median progression-free survival and overall survival were 10.1 (95% CI 8.6-11.6 months) and 24.1 (95% CI 11.2-37 months), respectively.

conclusionsTreatment with erlotinib significantly improves the clinical outcome in a subset of NSCLC patients with EGFRwt tumors. Further molecular analysis of such tumor specimens could provide a more comprehensive characterization of this particular group of patients. Nevertheless, the presence of other mutations should not prevent the treating physician from using erlotinib at later lines of salvage therapy for NSCLC patients.

Indexed as

Salvage TherapyAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellErbB ReceptorsFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedMutationEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsClinical characteristicsEGFR wild typeErlotinibGenomic aberrationsNSCLC

Identifiers

PMID28631135
OpenAlexW2691139715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.